Introduction {#s1}
============

The end of SARS-CoV-2 pandemic is still behind the horizon, as the total confirmed cases number rapidly rises. As of July 12, 2020, more than 12,500,000 cases of SARS-CoV-2 infections have been reported, out of which more than 560,000 ended lethally ([@B28]). The presence of chronic comorbidities may aggravate clinical findings and induce fatal outcome, as evidenced by the study on 44,672 confirmed cases, out of which 1023 had fatal outcome. Case fatality rates reported for patients suffering from chronic comorbidities including cardiovascular disease, diabetes, chronic respiratory disease, and hypertension (10.5%, 7.3%, 6.3,% and 6.0%, respectively) were much higher compared to case fatality a rate of 0.9% for patients without comorbid conditions ([@B19]). With the main focus of public health authorities on transmission prevention and development of vaccines and treatments, long-term consequences on the health of recovering and recovered patients remain subordinate. Radiological findings of COVID-19 patients indicate to pneumonia associated with rapidly developed pulmonary fibrotic changes, even in asymptomatic patients ([@B23]). Based on similarities between ongoing and previous coronavirus infections, excessive lung damage accompanied by fibrosis might result in functional disabilities, decreasing quality of life among survivors ([@B18]; [@B5]). The evolution of pneumonia to pulmonary fibrosis may vary, but the interval between the onset of symptoms and the development of pulmonary fibrosis may be relatively short, sometimes even just a few days ([@B23]), which indicate an urgent therapeutic approach to preserve pulmonary function. Besides, multi-organ injury affecting liver, kidneys, and heart, among others, which may eventually result in organ failure, is quite common among COVID-19 patients in intensive care units ([@B27]). SARS-CoV-2 either induces new cardiac pathologies, such as myocarditis, and/or leads to the exacerbation of existing ones ([@B17]), implying potential long-term cardiovascular effects of COVID-19. This might be important, especially for diabetic patients who already suffer from reduced lungs, hearth, and kidney function, making them particularly susceptible to cumulative organ injury during infection with SARS-CoV-2. With that in mind, we would like to voice our concerns over chronic implications following recovery from COVID-19, especially not only in diabetic but also in non-diabetic patients, and to indicate that some preventive measures could be undertaken by application of DPP-4 inhibitors.

Implications of DPP-4 Inhibition in Multi-Organ Injury Caused by COVID-19 {#s2}
=========================================================================

The potential role of DPP-4 in the pathogenesis of COVID-19 is a subject of the ongoing debate. Various authors emphasized anti-inflammatory properties of DPP-4 inhibitors with conflicting opinions on whether these effects are beneficial or detrimental in patients with COVID-19 ([@B6]; [@B7]; [@B9]; [@B11]; [@B14]; [@B15]; [@B20]). In addition, [@B24] pointed to well-known anti-fibrotic activity, while [@B4] further expanded on the topic by reflecting on cardioprotective effects of DPP-4 inhibitors. However, considerations made in both articles regarding the involvement of DPP-4 as a viral entry receptor, which are based on *in silico* predictions ([@B26]), are highly unlikely and in contradiction with experimental evidence ([@B16]; [@B30]).

Amplified and aberrant immune response to SARS-CoV-2 infection causes pulmonary injury triggering defensive pro-fibrotic mechanisms, as a result of simultaneous tissue remodeling by activated myofibroblasts and migrating fibroblasts, which possess on their surface dipeptidyl peptidase-4 (DPP-4)/CD26. In fact, inflammation is tightly interconnected with fibroblast activation, migration, and proliferation. However, although host immune response has crucial role in COVID-19 pathology, opinions on the use of anti-inflammatory therapies, especially in critically ill patients, are conflicting ([@B21]).

DPP-4 inhibitors are able to suppress inflammatory signalling and proliferation of vascular smooth muscle cells ([@B29]), which are important players in the reversible phase of pulmonary vascular remodeling. We have indicated the possibility that DPP-4 inhibitors might prevent fibrosis and delay or suppress the entry to the irreversible phase of vascular remodeling in pulmonary hypertension by reducing the activity of pro-fibrotic mediators, proliferation, and migration of fibroblasts ([@B3]). These pleiotropic anti-inflammatory effects of DPP-4 inhibitors are incomparable to standard anti-inflammatory therapies (i.e., corticosteroids) and might be useful in the therapy of COVID-19 due to their other favorable effects, especially after the clinical findings, suggesting the lack of benefit from corticosteroids and even indicating to deleterious effects accompanied with late complications ([@B22]). [**Figure 1**](#f1){ref-type="fig"} depicts the proposed mechanism of beneficial effects of DPP-4 inhibition on SARS-CoV-2 damaged lungs and other organs.

![Simplified mechanism of possible beneficial effects of DPP-4 inhibition through its anti-inflammatory, anti-proliferative, and anti-fibrotic actions, which counteract detrimental COVID-19 repercussions.](fphar-11-01185-g001){#f1}

In addition, we have pointed to many beneficial pleiotropic effects of DPP-4 inhibitors with protective role in renal and cardiovascular disorders as specific entities or type 2 diabetes mellitus associated comorbidities including myocardial regeneration. DPP-4 inhibitors exert these effects by reducing degradation of stromal cell--derived factor-1, which enhances homing of endothelial progenitor cells and ameliorates functional myocardial reparation outcome ([@B2]; [@B25]).

Recent reports clearly indicate that both hypertension and diabetes represent special risk factor as comorbidities with COVID-19 ([@B19]). Accordingly, [@B13] continued to suggest that patients with hypertension, who are prescribed either ACE inhibitors or angiotensin receptor antagonists known to increase ACE2 expression, might be at greater risk for severe COVID-19 infection and, therefore, should be monitored for ACE2-modulating medications. In contrast with ACE2-modulating medications, we have offered the hypothesis that DPP-4 inhibitors act in prevention/treatment of pulmonary fibrosis, heart, and kidney injury, and since they may be a long-term consequence caused by COVID-19, it is reasonable to expect that DPP-4 inhibitors might be beneficial in alleviating long-term consequences of COVID-19. [@B12] conducted a case-control study revealing that T2DM patients with COVID-19 had similar disease outcomes, regardless of therapy with DPP-4 inhibitors. Nonetheless, they advocate to DPP-4 inhibition as a valid therapeutic option due to optimal safety profile in comparison to other T2DM medications. Since DPP-4 inhibitors are one of the mainstream medications for the treatment of diabetes mellitus type 2, with demonstrated safety and tolerability ([@B10]; [@B8]; [@B12]), it would be rather undemanding to monitor the effect of DPP-4 inhibitors on long-term consequences on the health of COVID-19 recovering or recovered patients. We urge the scientific community to do exactly this.

Conclusion {#s3}
==========

In conclusion, the main purpose of this article is to raise the awareness that the end of SARS-CoV-2 pandemic will not necessarily be the end of our fight with COVID-19, since the long-term consequences of excessive lung, heart, and kidney injury in continuously increasing number of patients are yet to be seen. To the best of our knowledge, we are the first to hypothesize that DPP-4 inhibitors might emerge as a valuable asset in the alleviation of COVID-19 long-term repercussions following patients' recovery, given their favorable effects in protection and tissue regeneration. Administration of DPP-4 inhibitors to COVID-19 patients with ongoing type 2 diabetes mellitus could be advisable, as they are capable to benefit from effects on glycemic control, but also from protective anti-inflammatory, anti-proliferative and anti-fibrotic effects in the lungs, hearth, and kidneys. At the end of twentieth century the concept of ʹʹone molecule-one target-one diseaseʹʹ shifted toward multitarget drugs able to control complex diseases ([@B1]). DPP-4 inhibitors are capable of simultaneously treating both diabetes and its multiple complications. The mentioned effects of DPP-4 inhibitors are expected to be beneficial for some or even all SARS-CoV-2--infected patients, and we propose them as potential adjunctive treatment option aimed to alleviate COVID-19 long-term complications, especially knowing that millions of people will likely be affected by COVID-19.
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